Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) were down 5.9% on Monday . The stock traded as low as $0.16 and last traded at $0.16. Approximately 764,433 shares traded hands during trading, an increase of 56% from the average daily volume of 490,169 shares. The stock had previously closed at $0.17.
COPYRIGHT VIOLATION WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/4248597/hemispherx-biopharma-heb-shares-down-5-9.html.
About Hemispherx BioPharma (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Story: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.